期刊文献+

4-(4,6-二吗啉-1,3,5-三嗪-2-基)苯胺的合成

Synthesis of 4-( 4,6- dimorpholino- 1,3,5- triazin- 2- yl) aniline
下载PDF
导出
摘要 目的合成4-(4,6-二吗啉-1,3,5-三嗪-2-基)苯胺。方法三氯聚氰与吗啉在冰浴条件下经取代反应制得4,4’-(6-氯-1,3,5-三嗪-2,4-二基)二吗啉,再与苯胺-4-硼酸频那醇酯经Suzuki反应制得4-(4,6-二吗啉-1,3,5-三嗪-2-基)苯胺。结果与结论结构经核磁及质谱确证,总收率约61.7%。 Objective To synthesize 4 - (4,6 - dimorpholino - 1,3,5 - triazin - 2 - yl ) aniline. Methods 4,4' - ( 6 - chloro - 1,3,5 - triazine - 2,4 - diyl ) dimorpholine was synthesized with 2,4,6 - trichloro - 1,3,5 - triazine anti mor- pholine by substitution reaction under ice bath,and then reacting with amino - phenyl -4 - boronic acid pinacol ester to ob- tain 4 - ( 4,6 - dimorpholino - 1,3,5 - triazin - 2 - yl ) aniline by Suzuki reaction. Results and Conclusion The structure was confirmed by I H -NMR and ESI -MS,the overall yield was 61.7%.
作者 矫春丽 陈彤
出处 《药学研究》 CAS 2014年第4期242-243,共2页 Journal of Pharmaceutical Research
关键词 三氯聚氰 4-(4 6-二吗啉-1 3 5-三嗪-2-基)苯胺 中间体 合成 2,4,6 - trichloro - 1,3,5 - triazine 4 - ( 4,6 - dimorpholino - 1,3,5 - triazin - 2 - yl ) aniline Interme-diates Synthesis
  • 相关文献

参考文献6

  • 1Venkatesan AM,Dehnhardt CM,Delos Santos E. Bis (morpholino-1,3,5-triazine) derivatives:potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors:discovery of compound 26(PKI-587),a highly efficacious dual inhibitor[J].Journal of Medicinal Chemistry,2010,(06):2636-2645.
  • 2唐琰,贡岳松,徐云根,尤启冬.mTOR抑制剂的研究概况[J].有机化学,2011,31(7):1144-1154. 被引量:11
  • 3宣伟,邵藤,李义平,张三奇.PI3K/mTOR双重抑制剂的研究进展[J].现代药物与临床,2012,27(2):133-137. 被引量:4
  • 4Dehnhardt CM,Venkatesan AM,Chen Z. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors[J].Bioorganic & Medicinal Chemistry Letters,2011,(16):4773-4778.
  • 5Mallon R,Feldberg LR,Lueas J. Antitumor efficacy of PKI-587,a highly potent dual PI3K/mTOR kinase inhibitor[J].Clinical Cancer Research,2011,(10):3193-3203.
  • 6Venkatesan AM,Chen Z,dos Santos O. PKI-179:an orally efficacious dual phosphatidylinositol-3-kinase (PI3 K)/mammalian target of rapamycin (mTOR) inhibitor[J].Bioorganic & Medicinal Chemistry Letters,2010,(19):5869-5873.

二级参考文献87

  • 1Heitman, J.; Movva, N R.; Hall, M N. Science 1991, 253, 905.
  • 2Cafferkey, R.; Young, P. R.; McLaughlin, M. M.; Bergsma, D. J.; Koltin, Y.; Sathe, G. M.; Faucette, L.; Eng, W. K.; Johnson, R. K.; Livi, G. P. Mol. Cell. Biol. 1993, 13, 6012.
  • 3Brown, E. J.; Albers, M. W.; Shin, T. B.; Ichikawa, K.; Keith, C. T.; Lane, W. S.; Schreiber, S. L. Nature 1994,369, 756.
  • 4Donnelly, J. G.; Soldin, S. J. Clin. Biochem. 1994, 27, 3672.
  • 5Wiederrecht, G. J.; Sabers, C. J.; Brunn, G. J.; Martin, M. M.; Dumont, F. J.; Abraham, R. T. Prog. Cell Cycle Res. 1995, 1, 53.
  • 6Helliwell, S. B.; Wagner, P.; Kunz, J.; Deuter-Reinhard, M.; Henriquez, R.; Hall, M. N. Mol. Cell. Biol. 1994, 5, 105.
  • 7Jacinto, E.; Hall, M. N. Nat. Rev. Mol. Cell. Biol. 2003, 4, 117.
  • 8Gingras, A. C.; Raught, B.; Sonenberg, N. Genes Dev. 2001, 15, 807,.
  • 9Andrade, M.; Bork, P. Nat. Genet. 1995, 11, 115.
  • 10Asnaghi, L.; Bruno, P.; Priulla, M.; Nicloin, A. Pharmacol. Res. 2004, 50, 545.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部